SCHOTT Pharmaceutical Systems helps people around the world protect, access and use the medicine they need as safely and conveniently as possible.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
SCHOTT Pharma is a leading global provider of pharmaceutical packaging solutions, specialising in primary drug containment solutions and delivery systems for injectable medications. Headquartered in Mainz, Germany, and operating in 14 countries, the company leverages more than a century of expertise in glass science and engineering to serve pharmaceutical and biotechnology clients worldwide.
With 100 years of experience, SCHOTT Pharma offers an extensive product portfolio, including vials, syringes, cartridges, and ampoules, while upholding uncompromising quality and continuous innovation.
SCHOTT Pharma’s core business is manufacturing advanced primary packaging for injectable drug products. The portfolio is divided into Drug Containment Solutions (e.g. vials, cartridges, ampoules) and Drug Delivery Systems (prefillable syringes and related devices).
All products are made to stringent quality standards using high-performance materials like Type I borosilicate glass and medical-grade cyclic olefin copolymer.
Prefillable syringes (PFS) serve as both the storage container and the delivery device for injectable drugs, supplied sterile and ready to fill. SCHOTT Pharma offers PFS in premium glass (the syriQ® line) as well as in advanced polymer (the SCHOTT TOPPAC® range). These syringes provide a highly stable, long-term drug storage solution and enable safe, convenient injections for patients and caregivers.
Whether made from glass or cyclic olefin copolymer (COC) polymer, the syringes are engineered to maintain drug stability (even for sensitive biologics or vaccines) and to withstand special conditions like deep-cold storage for mRNA-based therapies.
By eliminating most preparation steps (the syringe is pre-sterilised and ready to use), these systems help reduce the risk of dosing errors, contamination, and drug waste during administration.
Pharmaceutical cartridges are small cylindrical containers (for devices like pen injectors and pumps) that enable accurate multi-dose delivery. Crafted from high-quality glass tubing, SCHOTT Pharma’s cartridges are known for robust construction and exceptionally accurate dosing performance.
They fit a wide range of injection devices to ensure smooth operation and patient safety. SCHOTT Pharma provides ready-to-use cartridges under its cartriQ® brand, including specialised designs for different drug requirements. For instance, double-chamber cartridges allow convenient reconstitution of lyophilised drugs, and break-resistant cartridges withstand high pressure or shock during use.
Standard cartridges come in various sizes and can be delivered sterile to streamline filling operations. With precision manufacturing and strict tolerances, these cartridges deliver consistent doses and integrate seamlessly into devices like insulin pens or auto-injectors.
Glass vials are a cornerstone of SCHOTT Pharma’s product range, used to contain injectable liquids, lyophilised drugs, and vaccines. SCHOTT Pharma’s vials are made from Type I borosilicate glass, offering high chemical resistance to minimise drug-container interactions. This ensures that medications – including sensitive biologics – remain stable over shelf life without significant leachables or pH shifts.
The vials have tight dimensional tolerances and superior cosmetic quality to support efficient high-speed filling and secure container closure integrity. For example, the adaptiQ® system provides ready-to-use vials in nest-and-tub formats for streamlined fill-finish processing.
SCHOTT Pharma has also developed innovative vial solutions under its EVERIC® family to meet specialised needs. EVERIC® vials feature ultra-clean inner surfaces and other enhancements to improve drug stability and safety.
For instance, EVERIC® pure vials have a homogeneous inner glass surface for unmatched drug stability. There are also variants for specific applications under the EVERIC® concept – for example, vials for deep-frozen biologics, highly sensitive formulations, or unique identifiers to support track-and-trace of individual containers. This modular approach helps clients choose optimal vials for their needs while ensuring compatibility with standard filling lines.
SCHOTT Pharma produces classic glass ampoules, reflecting the company’s long heritage. Ampoules are sealed single-dose containers opened by breaking the neck. SCHOTT Pharma’s ampoules are made from Type I glass with high chemical resistance and precise dimensions, ensuring drug stability until the point of use. The company also offers safety-enhanced versions: easyOPC ampoules have a scored neck for easier, controlled opening, and Anti-Counterfeiting (AC) ampoules use unique ring markings to deter tampering and fraud.
Beyond its products, SCHOTT Pharma offers value-added services to support clients from early drug development through commercialisation. Experts assist with everything from packaging design and material selection to laboratory analytics and regulatory filings, ensuring the packaging works optimally with the drug and meets compliance requirements. The company also emphasises sustainability in packaging, collaborating with customers to reduce carbon footprint and adopt eco-friendly practices.
SCHOTT Pharma addresses emerging industry challenges through targeted packaging solutions aligned with current trends. For example, as biologic drugs and biosimilars become more common, the company drives container innovation to maintain their stability (minimising glass delamination, protein interactions, etc.).
It has also developed solutions for mRNA vaccines and other therapies requiring low-temperature storage, ensuring containers withstand ultra-cold conditions and freeze–thaw cycles without integrity loss. To facilitate self-administration, SCHOTT Pharma provides options for delivering large-volume biologics – such as optimised polymer syringe systems – that accommodate high-viscosity drugs and enable high-speed, quality-consistent filling.
Through continuous innovation in these areas, SCHOTT Pharma serves as a strategic partner to drug makers, helping overcome packaging hurdles as new therapies come to market.
SCHOTT Pharma prides itself on quality and technical innovation. All products are manufactured under rigorous quality management, with state-of-the-art automation and inspection ensuring consistency.
For example, SCHOTT Pharma’s syringe lines undergo 100% camera inspection to achieve extremely low defect rates, supporting an efficient fill-and-finish process. Backed by a deep research and development (R&D) heritage, the company continually improves materials and designs – from ultra-pure vial coatings to digital traceability features. Today, SCHOTT Pharma remains at the forefront of primary packaging technology.
Fractography (fracture analysis) is an underestimated technique which makes it possible to objectively determine the true root cause of glass breakage.
A critical issue that may occur with IV drugs is microbial contamination.
The new vial concept offers pharmaceutical companies a choice of features that can be flexibly combined, addressing individual needs and requirements in the context of the containers themselves and the efficient processing of such primary packaging. The three respective features are introduced to the market by EVERIC™.
The recent spike in market recalls for injectable drug products due to visible flaky particles associated with 'glass delamination' demonstrates the need to solve these problems.
Protecting medication from undesired interactions with the surrounding environment and preserving their efficacy during shelf life is one of the most pressing challenges for the pharmaceutical industry.
Achieving a consistently high surface quality is a matter of process control. Theoretically, every vial should have the same inner surface quality if the process is stable.
SCHOTT Pharma’s new facility in Lukacshaza, Hungary, will increase the company’s capacity to deliver high-value solutions.
SCHOTT Pharma will build a $371m pre-fillable syringe manufacturing facility in Wilson, North Carolina, expanding to the US market.
SCHOTT opened the first GMP-compliant pharmaceutical packaging production facility in Russia in May 2011. The plant is located at Zavolzhe near Nizhny Novgorod city in Russia.
Christian Mias, born in Iserlohn in 1974, will succeed Andreas Reisse starting May 1st.
The global large-volume injectors market is expected to witness substantial growth over the next decade, driven by factors such as the rising prevalence of chronic diseases, a shift towards homecare, and technological advancements in injector devices.
As the biologics market continues to expand, fuelled by breakthroughs such as cell and gene therapies, drug developers face increasing demand for safe, patient-friendly delivery and administration solutions.
As biologic therapies continue to rise for treating cancer, autoimmune, and neurological diseases, drug containment and delivery solutions are evolving to meet these new therapeutic demands.
The US Pharmacopeia (USP) has proposed a revision to General Chapter Container—Glass, which provides specifications for glass containers used in the pharmaceutical industry. These modifications aim to modernise tests and test methods alongside specifications within the chapter. The underlying goal is to create additional flexibility for packaging and storage requirements. However, many experts in the pharmaceutical industry believe that this is a short-sighted move.
With vials capable of holding up to 2 billion vaccination doses, SCHOTT is supporting the world’s struggle against Covid-19.
The CEOs of SCHOTT, Stevanato Group, and Gerresheimer have pledged the ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment developed, no matter the patient or region of the world they reside.
Each drug formulation is unique, as is every patient. Especially high-potency medicines breaking into the market have exacting pharma packaging must guarantee drug stability.
The 2.25mL long syringe was manufactured for highly viscous biologics, administered by using an autoinjector.
By breaking ground, speciality glass manufacturer SCHOTT has given the preliminary signal for the erection of a production facility for sterile polymer pharmaceutical primary packaging at its Müllheim site, Germany.
SCHOTT Pharmaceutical Systems has announced it will be exhibiting at CPhI Worldwide 2019.
The future of augmented reality (AR) and mixed reality (MR) is right in front of your eyes. SCHOTT has unveiled the latest addition to SCHOTT RealView™, a product portfolio of high-quality optical glass wafers designed for the realisation of a new era of consumer-grade smart glasses.
International technology group SCHOTT and French engineering firm SINCAD have signed an exclusive cooperation and development agreement aimed at strengthening SCHOTT’s expertise in the field of camera inspection systems.
People undergoing facial plastic surgery expect flawless results. Yet aesthetic injections are not a simple task. That is where SCHOTT TOPPAC® cosmetic syringes come into play.
Complex biological drugs offer hope for some of the hardest-to-treat conditions, from cancer to chronic disease. That promise comes with challenges. For example, biologics requires special packaging that will maintain the drug stability and ensure patient safety.
SCHOTT is to expand its TopPac polymer syringes range with through launching a 20ml unit that can be used in combination with syringe pumps for infusion therapy.
SCHOTT has announced that it plans to achieve further growth in its prefillable syringe line.
SCHOTT is to launch SCHOTT Vials DC, which are pharmaceutical vials that, for the first time ever, allows for the risk of delamination to be determined based on threshold values.
With adaptiQ, SCHOTT will be unveiling a new concept of ready-to-use pharmaceutical vials that has been modified in close cooperation with filling line manufacturers to meet the process requirements of the pharmaceutical industry.
SCHOTT Pharmaceutical Systems has unveiled plans for the significant expansion of its Hungarian site Lukácsháza, which manufactures pharmaceutical primary packaging.
SCHOTT Pharmaceutical Systems has presented the world's first cartridges developed specifically for the use on high-speed filling lines at the pharmaceutical trade fair Interphex in New York.
SCHOTT has been expanding its manufacturing capacity for small size (1ml to 10 ml) SCHOTT TopPac® syringes in order to address the increasing worldwide demand for prefillable polymer syringes.
SCHOTT Pharmaceutical Systems has unveiled plans for expanding production capacities by 20% at its facility in Bekasi, Indonesia.
SCHOTT has expanding its range of analyses offered due to an increasing demand for laboratory services related to 'extractables and leachables' ('E&L').
SCHOTT continues to strengthen its position in the Asian pharmaceutical market with the opening of a high-tech facility in India.
SCHOTT Pharmaceutical Packaging has released a new, free-to-download white paper which explores ways to minimize the delamination risk of glass containers.
From 12-18 May, SCHOTT presented its innovative solutions in the area of parenteral packacking for the pharmaceutical industry under the motto 'Your Trusted Partner for Quality Packaging Solutions, Worldwide' at the Interpack 2011 event in Düsseldorf, Germany. On two floors and an
The German technology group SCHOTT and the Japanese company Naigai Glass Industry recently founded a joint venture for pharmaceutical packaging activities in Japan, which came into effect from 1 October 2010. The new company is called SCHOTT NAIGAI K.K. and is based in Osaka, Japan, where Naiga
New drugs generate new challenges in the field of pharmaceutical packaging. "Biomolecules, for instance, are being used today in over 50% of all product developments in pharmaceutical therapy," says Dr Claudia Dietrich, product manager for vials and coating at SCHOTT in St. Gallen, Switzerlan
Recently, the US Food and Drug Administration (FDA) addressed a warning to a US pharmaceuticals company, when third-party manufactured glass vials were found to contain glass particles upon inspection. SCHOTT Pharmaceutical Packaging Division, part of the multinational technology-based
With a new manufacturing facility for premium-quality ampoules and vials in Zavolzhe, near the Russian city of Nizhny Novgorod, the German technology company and global quality leader SCHOTT will extend its leading position in the area of high-quality pharmaceutical packaging in Russia. At the 'P
SCHOTT Pharma's prefilled syringes (PFS), whether made from glass or advanced polymer, provide a stable, long-term storage solution for drugs while offering a safe and convenient delivery system for both patients and clinicians. With fewer manual steps required compared to conventional packaging, PFS significantly lower the risk of medical errors and infections, prioritising the safety of healthcare professionals and patients alike.
Robust, reliable, and compatible with a wide range of devices, SCHOTT Pharma's cartridge selection ensures precise drug dispensing across diverse medical scenarios.
Made of Type I Borosilicate Glass, SCHOTT Pharma's vials provide exceptional chemical resistance, safeguarding liquid drug formulations during storage. With precise dimensions and superior cosmetic quality, they facilitate an effective fill-and-finish procedure while ensuring container closure integrity.
Manufactured using Type I Borosilicate Glass, SCHOTT Pharma ampoules offer high chemical resistance, accurate dimensions, tight cosmetic control, and drug stability from production to administration. With a focus on quality and safety, our ampoules provide the optimal solution for storing and delivering drugs with confidence.
SCHOTT Pharma offers tailored drug containment and delivery services, providing complete packaging solutions to meet your specific needs. Our comprehensive suite of services includes design, prototyping, and GMP-compliant documentation for primary and related packaging components.
SCHOTT Pharma offers data-driven analytical services that validate the suitability of containment solutions for your specific drug products. Our experts thoroughly assess material compliance, functionality, and drug-container interaction to ensure optimal container selection.
SCHOTT Pharma provides efficient fill-and-finish services, specialising in small-sample filling and closing during the early stages of production. Our expertise extends to conducting analytics to ensure seamless compatibility between packaging, containers, and line equipment.
SCHOTT Pharma provides comprehensive regulatory services to assist drug product and medical device owners in gathering the necessary information for registering containment systems. Our expertise ensures the global availability of information, complying with evolving international regulations, standards, as well as country-specific laws and guidelines.
